SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Q3 net loss $44.3M

Spero Therapeutics, Inc. · 8-K filed Nov 12, 2026 at 16:43 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 12, 2026 at 16:43 ET

Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76 per share), compared to $5.4 million revenue and a $7.4 million loss in Q3 2025. The wider loss reflects a $35 million upfront payment to Innovent for in-licensing SP001, a Phase 2-ready anti-CD40L antibody for IgG4-related disease. Cash of $107.9 million funds operations into H2 2029, and the company has shifted focus from tebipenem HBr (now partnered with GSK) to immune-mediated diseases.

  • No revenue in Q3 2026 vs $5.4M in Q3 2025
  • Net loss of $44.3M ($0.76/share) vs $7.4M ($0.13/share) in Q3 2025
  • R&D expenses $38.2M, including $35M upfront to Innovent for SP001 license
  • Cash and equivalents $107.9M as of Sep 30, 2026, sufficient into H2 2029

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access